Fidia, a multinational pharmaceutical company, agreed to acquire a portfolio of pharmaceutical products from Sanofi, a French multinational pharmaceutical company. Financial terms were not disclosed. “The acquisition confirms our will, despite the tough challenge created by Covid-19, to continue investing in core pharmaceutical business as part of our international growth, not only thanks to consolidation in the areas in which we are leaders, but also through more solid positioning as a result of entering different therapeutic areas. Furthermore, the acquisition represents an opportunity to strengthen managerial resources, under theframeworkof a sustainable annual average growth: once again, a development model that is characterised by the ability to face the challenges and seize the opportunities of tomorrow, in the long-term, although the world's economies have been particularly battered," Carlo Pizzocaro, Fidia President and CEO.